ResMed Inc. Enters Accelerated Share Repurchase Agreement

ResMed Inc. has entered into an accelerated share repurchase (ASR) agreement with Citibank, N.A. for $450.0 million. This repurchase is part of a pre-approved authorization to repurchase up to 20,000,000 shares of common stock, originally approved in February 2014. The ASR will be funded by proceeds from the sale of ResMed's MatrixCare business and existing cash reserves. This transaction aligns with the company's previously issued guidance for fiscal year 2027. ResMed will pay $450.0 million to Citibank on September 3, 2026, and is expected to receive an initial delivery of shares representing 80% of the ASR amount, based on the stock's closing price on September 2, 2026. The final number of shares repurchased will be determined by the volume-weighted average price during the ASR term, subject to discounts and adjustments. Final settlement is anticipated in December 2026.